Compare · BSX vs IIN
BSX vs IIN
Side-by-side comparison of Boston Scientific Corporation (BSX) and Intricon Corporation (IIN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and IIN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.39B, about 558.7x IIN ($129.6M).
- BSX has hit the wire 12 times in the past 4 weeks while IIN has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for IIN).
- Company
- Boston Scientific Corporation
- Intricon Corporation
- Price
- $48.71+0.31%
- $24.25+0.06%
- Market cap
- $72.39B
- $129.6M
- 1M return
- -13.91%
- -
- 1Y return
- -51.31%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Intricon Corporation
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology, and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers. In addition, it offers professional audio headset products used for emergency response needs in the fire, law enforcement, safety, aviation, and military markets; and a line of miniature ear-and head-worn devices used by performers and support staff in the music and stage performance markets. The company sells its hearing device products, and medical and professional audio communications products directly to hearing instrument manufacturers, distributors, and partnerships; and microphone products to the radio communication and professional audio industries, as well as markets and sells hearing aid devices directly to consumers through direct mail advertising, Internet, and call center. The company was formerly known as Selas Corporation of America and changed its name to IntriCon Corporation. The company was incorporated in 1930 and is headquartered in Arden Hills, Minnesota.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest IIN
- SEC Form 15-12B filed by Intricon Corporation
- SEC Form SC 13D/A filed by Intricon Corporation (Amendment)
- Intricon Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4: Giordano Nicholas A gifted 4,000 shares and returned 110,925 shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Philip Irving returned 16,327 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gorder Mark Stephen returned 373,709 shares to the company, closing all direct ownership in the company
- SEC Form 4: Rider Heather D. returned 9,121 shares to the company, closing all direct ownership in the company
- SEC Form 4: Huggenberger Raymond returned 11,154 shares to the company, closing all direct ownership in the company
- SEC Form 4: Pepski Kathleen P. returned 3,586 shares to the company, closing all direct ownership in the company
- SEC Form 4: Lutgen Annalee was granted 2,271 shares and returned 9,702 shares to the company, closing all direct ownership in the company